-
EAU 2025 | CUHK’s Peter Chiu and Team Highlight Advances in Precision Biopsy and Standardized Treatment for Prostate Cancer
Prostate cancer remains one of the most prevalent malignancies threatening men’s health worldwide. A major research focus today lies in developing accurate screening and diagnostic strategies that minimize the invasiveness and psychological burden of biopsy procedures. Landmark studies like SMART and PRECISION aim to address these challenges. At the 2025 European Association of Urology (EAU)…
-
Live from the 2025 EASL Liver Cancer Summit | Studio Connection Spotlight
We’re honored to present an exclusive dialogue featuring Professor Julien Calderaro, President of the 2025 EASL Liver Cancer Summit, and Professor Jian Zhou from Zhongshan Hospital, Fudan University and the President of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE).
-
2025 South-North Forum | Prof. Jin Feng: Breaking Barriers and Leading Innovation – A New Chapter in Breast Cancer Research
The 2025 South-North Forum – 7th Breast Cancer forum was recently held in Shanghai, co-hosted by the Shanghai Anti-Cancer Association and the China Anti-Cancer Association Committe of Breast Cancer Society(CACA-CBCS), with support from the Chinese Medical Association, Chinese Society of Oncology- Breast Oncology(CMA-CSO-BO). The event was co-organized by Fudan University Shanghai Cancer Center and The…
-
Professors Jeremy Teoh and Yige Bao Share Research Highlights and Clinical Insights, as “Chinese Excellence” Shines on Europe’s Academic Stage
With diagnostic and therapeutic technologies advancing rapidly, precision treatment strategies for genitourinary malignancies such as urothelial carcinoma and prostate cancer are evolving with growing momentum. At the recent 2025 Annual Meeting of the European Association of Urology (EAU25), Professor Jeremy Teoh of The Chinese University of Hong Kong and Professor Yige Bao of West China…
-
SGBCC 2025 | Dr. Man Li: Chinese Innovation is Shaping Clinical Practice and Amplifying the Voice of China on the Global Stage
The 19th St. Gallen Breast Cancer Conference (SGBCC 2025) took place from March 12–15, 2025, in Vienna—the world-renowned capital of music. A major highlight of the event was the “Voice of China” session, where international experts gathered to exchange insights on the development of innovative therapies from China. On this occasion, Oncology Frontier sat down…
-
SGBCC Voice of China丨Dr. Yongmei Yin: Steady Progress Leads to Breakthroughs—Bridging East and West to Shape a New Era in Breast Cancer Care
The 19th St. Gallen Breast Cancer Conference (SGBCC 2025) recently concluded in Vienna, and once again, voices from China stood out on the global stage. Dr. Yongmei Yin from Jiangsu Provincial Hospital made history as the first Chinese female expert to join the St. Gallen International Consensus Panel on Early Breast Cancer, actively participating in…
-
Academician Binghe Xu: Lerociclib Ushers in a New Chapter for HR+/HER2− Advanced Breast Cancer Treatment
01 Current Landscape and Challenges in HR+/HER2− Breast Cancer: Clinical Use and Safety Considerations of CDK4/6 Inhibitors Oncology Frontier: CDK4/6 inhibitors have played an increasingly pivotal role in the treatment…
-
Dr. Lu Gan: Strategic Option of HDAC Inhibitors
The Evolution of Epigenetics and the Mechanism and Role of HDAC Inhibitors 1. The Evolution of Epigenetics Epigenetics is a subfield of genetics that studies heritable changes in gene expression…
Connecting Medical Expertise through Media